Efficacy of nonsolvent flower pollen extracts in healthy women with urinary incontinence: A randomized, double-blind, placebo-controlled, parallel study

Marc Moulin, Erin D Lewis, David C. Crowley, Colleen E. May, Malkanthi Evans
{"title":"Efficacy of nonsolvent flower pollen extracts in healthy women with urinary incontinence: A randomized, double-blind, placebo-controlled, parallel study","authors":"Marc Moulin, Erin D Lewis, David C. Crowley, Colleen E. May, Malkanthi Evans","doi":"10.1097/cu9.0000000000000248","DOIUrl":null,"url":null,"abstract":"\n \n \n Urinary incontinence (UI) is a debilitating and common condition that adversely affects quality of life. Prescriptive and surgical approaches for managing UI symptoms may result in undesirable risks and complications. This randomized, double-blind, placebo-controlled, parallel study investigated the efficacy of 2 nonsolvent flower pollen extracts on UI in healthy women.\n \n \n \n One-hundred and fourteen women aged 40–75 years who scored ≥5 on the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-SF) were randomized to receive either Graminex® RCT Fem™ UI, Graminex® PollenBerry®, or placebo for 24 weeks. The primary outcome was the change in the ICIQ-SF score between the trial and placebo groups after 24 weeks of supplementation. The secondary outcomes included changes in the frequency of nocturia (recorded in 3-day void diaries) and 24-hour leakage volume (assessed via pad weight) after 6, 12, 18, and 24 weeks of supplementation and changes in stress-induced urinary leakage volume (after completion of a provocative maneuver challenge) after 24 weeks of supplementation.\n \n \n \n All the groups demonstrated improvement in ICIQ-SF scores at week 24 (p < 0.001). The RCT Fem™ UI group had the greatest improvement in ICIQ-SF scores (−4.07 ± 3.4), followed by the PollenBerry® group (−3.34 ± 2.87) and placebo group (−2.61 ± 3.52). The RCT Fem™ UI group had corresponding improvements in 24-hour leakage volume (−17.68 ± 39.84 g) and frequency of nocturia (−0.52 ± 1.26) (p ≤ 0.05). PollenBerry® supplementation significantly improved stress-induced urinary leakage volume (−7.12 ± 15.64 g) at week 24. The study products demonstrated safe hematological and chemical profiles.\n \n \n \n RCT Fem™ UI supplementation resulted in significant and clinically meaningful reductions in UI severity, with corresponding improvements in daily urinary leakage volume and frequency of nocturia. PollenBerry® significantly improved stress-induced urinary leakage volume, suggesting that it may be efficacious in women who are prone to stress UI. The study products were safe and well tolerated in this population.\n","PeriodicalId":510120,"journal":{"name":"Current Urology","volume":"36 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/cu9.0000000000000248","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Urinary incontinence (UI) is a debilitating and common condition that adversely affects quality of life. Prescriptive and surgical approaches for managing UI symptoms may result in undesirable risks and complications. This randomized, double-blind, placebo-controlled, parallel study investigated the efficacy of 2 nonsolvent flower pollen extracts on UI in healthy women. One-hundred and fourteen women aged 40–75 years who scored ≥5 on the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-SF) were randomized to receive either Graminex® RCT Fem™ UI, Graminex® PollenBerry®, or placebo for 24 weeks. The primary outcome was the change in the ICIQ-SF score between the trial and placebo groups after 24 weeks of supplementation. The secondary outcomes included changes in the frequency of nocturia (recorded in 3-day void diaries) and 24-hour leakage volume (assessed via pad weight) after 6, 12, 18, and 24 weeks of supplementation and changes in stress-induced urinary leakage volume (after completion of a provocative maneuver challenge) after 24 weeks of supplementation. All the groups demonstrated improvement in ICIQ-SF scores at week 24 (p < 0.001). The RCT Fem™ UI group had the greatest improvement in ICIQ-SF scores (−4.07 ± 3.4), followed by the PollenBerry® group (−3.34 ± 2.87) and placebo group (−2.61 ± 3.52). The RCT Fem™ UI group had corresponding improvements in 24-hour leakage volume (−17.68 ± 39.84 g) and frequency of nocturia (−0.52 ± 1.26) (p ≤ 0.05). PollenBerry® supplementation significantly improved stress-induced urinary leakage volume (−7.12 ± 15.64 g) at week 24. The study products demonstrated safe hematological and chemical profiles. RCT Fem™ UI supplementation resulted in significant and clinically meaningful reductions in UI severity, with corresponding improvements in daily urinary leakage volume and frequency of nocturia. PollenBerry® significantly improved stress-induced urinary leakage volume, suggesting that it may be efficacious in women who are prone to stress UI. The study products were safe and well tolerated in this population.
非溶剂型花粉提取物对健康女性尿失禁患者的疗效:随机、双盲、安慰剂对照、平行研究
尿失禁(UI)是一种使人衰弱的常见疾病,会对生活质量产生不利影响。治疗尿失禁症状的处方和手术方法可能会带来不良风险和并发症。这项随机、双盲、安慰剂对照、平行研究调查了两种非溶剂花粉提取物对健康女性尿失禁的疗效。 114名年龄在40-75岁之间、尿失禁国际咨询问卷-尿失禁简表(ICIQ-SF)得分≥5分的女性被随机分配到Graminex® RCT Fem™ UI、Graminex® PollenBerry®或安慰剂中,接受为期24周的治疗。主要结果是补充 24 周后试验组和安慰剂组之间 ICIQ-SF 分数的变化。次要结果包括补充 6、12、18 和 24 周后夜尿频率(记录在 3 天排尿日记中)和 24 小时漏尿量(通过尿垫重量评估)的变化,以及补充 24 周后压力引起的漏尿量(完成刺激性动作挑战后)的变化。 所有组别在第 24 周时的 ICIQ-SF 评分均有所改善(p < 0.001)。RCT Fem™ UI 组的 ICIQ-SF 评分改善幅度最大(-4.07 ± 3.4),其次是 PollenBerry® 组(-3.34 ± 2.87)和安慰剂组(-2.61 ± 3.52)。RCT Fem™ UI 组的 24 小时漏尿量(-17.68 ± 39.84 克)和夜尿次数(-0.52 ± 1.26)均有相应改善(p ≤ 0.05)。第24周时,补充 PollenBerry® 能明显改善压力引起的漏尿量(-7.12 ± 15.64 g)。研究产品的血液学和化学成分均符合安全标准。 服用 RCT Fem™ UI 补充剂后,尿频尿急的严重程度明显降低,每日漏尿量和夜尿次数也得到相应改善,具有临床意义。PollenBerry® 能明显改善压力引起的漏尿量,这表明它可能对容易出现压力性尿失禁的女性有效。该研究产品在此类人群中安全且耐受性良好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信